Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2993)	12/26/2007 5:21:52 PM
From: Icebrg	of 3044

Millennium Pharmaceuticals "outperform" Wednesday, December 26, 2007 6:31:38 AM ET Robert W. Baird NEW YORK, December 26 (newratings.com) - Analyst Christopher Raymond of Robert W Baird reiterates his "outperform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $18. In a research note published this morning, the analyst mentions that the November institutional prescription data released by Wolters Kluwer Health indicates WAC dollar sales of $22 million for Millennium Pharmaceuticals’ Velcade. Thus the drug’s WAC dollar sales are sequentially up 27% in the first two months of 4Q07, the analyst says. If this trend continues, Millennium Pharmaceuticals may generate $80 million in Velcade revenues in 4Q07, ahead of the consensus expectations, Robert W Baird adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next